Prestige Consumer Healthcare Inc Dossier
Qualitative Analysis
Business overview
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading developer, marketer, and distributor of over-the-counter (OTC) healthcare products. The company operates primarily in two segments: North American OTC Healthcare (representing 83.9% of net revenues in fiscal 2026) and International OTC Healthcare (representing 16.1%). Prestige focuses on niche consumer health categories, managing a diverse portfolio of well-known brands. Key brands include Monistat (vaginal anti-fungal), Summer's Eve (feminine hygiene), Clear Eyes (redness relief), Dramamine (motion sickness relief), and Compound W (wart removal). Approximately 63.7% of the company's total revenues are generated by brands holding the number one market position in their respective categories.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Addressing supply chain shortfalls and capacity constraints in the eye care segment (specifically Clear Eyes) through the acquisition of sterile ophthalmic manufacturer Pillar5 Pharma and onboarding additional third-party suppliers.
Expected impact: Rebuild retailer confidence, secure near-term supply, expand long-term production capacity, and return the segment to approximately 5% annual organic revenue growth.
Acquiring durable, high-margin, cash-generating over-the-counter (OTC) brands with strong consumer recognition to expand into new product categories and geographic markets.
Expected impact: Breathe Right becomes the largest brand in the portfolio, adding a new nasal strip category. LaCorium expands the therapeutic skin care platform in Australia.
Focusing marketing and product development on identifying underserved consumer needs and extending highly recognizable brand names to new products.
Expected impact: Broaden product categories, increase market share, and drive organic volume growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquire the iconic #1 brand synonymous with the nasal strip category, expanding Prestige's portfolio into a new category and establishing Breathe Right as its largest brand.
Financial impact: Expected to be margin-accretive (gross margin, EBITDA margin, and EPS) and generate strong incremental free cash flow to support rapid debt deleveraging. Net purchase price is approximately $900 million after $150 million in anticipated tax benefits.
Acquire a leading Australian therapeutic skin care platform (including Dermal Therapy and Flexitol brands) to expand Prestige's international OTC footprint.
Financial impact: LaCorium generated approximately $40 million in TTM revenue through February 28, 2026, and is expected to generate approximately $12 million in EBITDA including anticipated synergies once fully integrated.
Acquire a leading sterile ophthalmic manufacturer and current Clear Eyes supplier to secure near-term supply and expand long-term eye care production capacity.
Financial impact: Expected to be approximately neutral to EPS initially, while securing the supply chain for Clear Eyes (the largest revenue source for Pillar5).